148P - Metastatic site location may influence the diagnostic accuracy of plasma EGFR-mutation testing in NSCLC: A pooled analysis

Date 07 May 2017
Event ELCC 2017
Session Poster Display Session
Topics Non-Small-Cell Lung Cancer, Locally Advanced
Lung and other Thoracic Tumours
Presenter Francesco Passiglia
Citation Annals of Oncology (2017) 28 (suppl_2): ii52-ii55. 10.1093/annonc/mdx094
Authors F. Passiglia1, A. Listì2, N. Barraco2, A. Galvano2, D. Fanale2, L. Incorvaia2, V. Bazan2, C. Rolfo3, A. Russo2
  • 11. medical Oncology Unit, Department Of Surgical, Oncological And Oral Sciences, University Of Palermo, Palermo, Italy, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone", 90127 - Palermo/IT
  • 21. medical Oncology Unit, Department Of Surgical, Oncological And Oral Sciences, University Of Palermo, Palermo, Italy, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone", Palermo/IT
  • 32. phase I- Early Clinical Trials Unit, Oncology Department And Multidisciplinary Oncology Center Antwerp (moca), Antwerp University Hospital, Edegem, Belgium, University of Antwerp, Antwerp/BE

Abstract

Background

Recent studies evaluated the potential role of EGFR mutation testing by using circulating tumor DNA (ctDNA) isolated from plasma of NSCLC patients, overall showing a lower sensitivity compared with the standard tissue genotyping. However, it’s less clear if the presence of extrathoracic (M1b) disease may enhance the ability to identify EGFR mutations in plasma. This pooled analysis aims to evaluate the association between metastatic site location and sensitivity of ctDNA analysis.

Methods

Data from all published studies, that evaluated the sensitivity of plasma-based EGFR-mutation testing, stratified by metastatic site location (extrathoracic (M1b) vs intrathoracic (M1a)) were collected by searching in PubMed, Cochrane Library, American Society of Clinical Oncology, and World Conference of Lung Cancer, meeting proceedings. Pooled Odds ratio (OR) and 95% confidence intervals (95% CIs) were calculated for the ctDNA analysis sensitivity, according to the metastatic site location.

Results

A total of seven studies, with 1233 patients, were eligible. Pooled analysis showed that the sensitivity of EGFR-mutation testing by ctDNA was significantly higher in patients with extrathoracic disease (M1b) compared to patients with intrathoracic (M1a) disease (OR: 4.29; 95% CIs: 2.20 – 8.38).

Conclusions

These data suggest that the location of metastatic sites significantly influences the diagnostic accuracy of ctDNA analysis. Particularly the ability to identify EGFR activating mutations in plasma of NSCLC patients is significantly higher in the presence of M1b vs M1a disease. These observations could influence the clinical management of EGFR-mutated patients.

Clinical trial identification

N.A

Legal entity responsible for the study

Palermo University Hospital

Funding

Palermo University Hospital

Disclosure

All authors have declared no conflicts of interest.